- Q1 2024 Vir Biotechnology Inc Earnings Call TranscriptMay 02, 2024$9.18 (+5.03%)Earnings
- Q4 2023 Vir Biotechnology Inc Earnings Call TranscriptFeb 22, 2024$10.3 (+1.88%)Earnings
- Vir Biotechnology Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Vir Biotechnology Inc AASLD Late Breaking Data Update Call TranscriptNov 13, 2023
- Q3 2023 Vir Biotechnology Inc Earnings Call TranscriptNov 02, 2023$8.19 (+5.13%)Earnings
- Vir Biotechnology Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Vir Biotechnology Inc Earnings Call TranscriptAug 03, 2023$13.97 (-0.50%)Earnings
- Vir Biotechnology Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Vir Biotechnology Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Vir Biotechnology Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM TranscriptJan 10, 2023
- Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 18, 2022
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Vir Biotechnology Inc Corporate Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant TranscriptDec 07, 2021
- Vir Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
Vir Biotechnology Inc at JPMorgan Healthcare Conference Transcript
Okay. Great. Good afternoon. I'm Eric Joseph, senior biotech analyst with J.P. Morgan. And our next presenting company is Vir Biotechnology. And to start the presentation this afternoon is CEO, Marianne De Backer. There is a Q&A session after the presentation. (Conference Instructions) With that, Marianne, thanks for joining us.
Okay. Thank you. Thank you, Eric, and thank you, J.P. Morgan, for hosting Vir Biotechnology. Good afternoon, everyone, here in the room in San Francisco and everyone joining on the webcast. I'm Marianne De Backer, and I'm the CEO of Vir Biotechnology.
So 2024 is poised to be a truly transformational year for Vir because we are looking forward to data readouts from our clinical Phase 2 hepatitis delta program, our clinical Phase 2 hepatitis B program and our Phase 1 HIV T cell-based vaccine program. During this presentation, I will share more about Vir's leading clinical programs, about our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)